Highest-materiality recent filing
Hongchang International ceases shell company status, filing amendment clarifies
Filed Amendment No. 1 to 8-K dated Sep 7, 2023 to clarify cessation of shell company status.
Acquired all shares of Hongchang BVI for 415.6M new shares (80.1% of post-acquisition total).
Heyu Biological to acquire Hongchang BVI in reverse merger; 80.1% control to sellers
Issues 415,582,375 shares (80.1% of post-close total) to acquire Hongchang BVI, which owns Fujian food industrial park.
Heyu Bio receives SEC non-compliance letter; faces potential registration revocation
Received SEC letter dated Dec 17, 2021 (received Dec 30) citing non-compliance with Section 13(a) reporting.
On April 24, 2025, Ms. Qingqing Wang, the Board Secretary of the Company, notified the Board that she was resigning from the Board Secretary, effective as of April 24, 2025.
On April 24, 2025, Mr. Ban Siong Ang, a director and the Chairman of the Board of the Company, notified the Board that he was resigning from Chairman of the Board due to personal reasons, effective as of April 24, 2025.
Effective as of April 24, 2025, Mr. Zengqiang Lin, Chief Executive Officer, Chief Financial Officer, President and a director of the Company, was appointed as the Chairman of the Board of the Company.
Effective May 8, 2024, Ms. Wendy Li resigned as the Chief Financial Officer of Hongchang International Co., Ltd (the “Company”), due to personal reasons.
Effective May 8, 2024, Mr. Xingjia Gao resigned as a Director from the Board of the Company, due to personal reasons.
Effective May 8, 2024, Mr. Zengqiang Lin was appointed as the Chief Financial Officer of the Company, in addition to his appointments as the Chief Executive Officer and Director of the Company.
Effective March 27, 2024, Ms. Qingqing Wang was appointed as a Board Secretary of the Company by the Board.
Effective March 27, 2024, Mr. Stephan Truly Busch resigned as a director of Hongchang International Co., Ltd (the “Company”).
On February 17, 2023, the board of directors of Heyu Biological Technology Corporation (the “Company”) announced the appointment of Mr. Zengqiang Lin as an independent director of the Company, effective immediately.
On November 30,2021, Mr. Bo Lyu was appointed by the board of directors of Heyu Biological Technology Corporation (the “Company”) as the Company’s Chief Financial Officer, effective immediately.
Max materiality 0.95 · Median 0.35 · Most common event other_material